Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger

Objective Rituximab in combination with chemotherapy has been proven to increase progression-free and overall survival in follicular lymphoma (FL), but there is considerable interindividual variability in the response. Extrinsic pathway apoptosis triggered by death receptors seems to be involved in the mechanism of action of monoclonal antibodies. This study aimed to assess the association between TRAILR1/TRAIL polymorphisms (rs20575, rs20576, rs2230229, rs12488654) and rituximab response and the relationship with FASL rs763110, previously found to be associated with rituximab response. Patients and methods Polymorphisms were determined in a study cohort of 125 FL patients treated with rituximab as first-line treatment and correlated with response, which was scored according to the International Working Group Consensus Revised as complete response, partial response, stable disease, and progressive disease. Results No significant association with response was found for rs20576, rs2230229, and rs12488654 polymorphisms. In contrast, rs20575 GC/GG carriers were more partial/nonresponders (88.2%) than complete responders (72.5%), showing a trend toward statistical significance (P=0.064). In a multivariable setting, we found that female sex [odds ratio=0.355, 95% confidence interval (CI): 0.137–0.922, P=0.033] and the TRAILR1 rs20575 CC genotype (odds ratio=0.162, 95% CI: 0.035–0.757, P=0.021) were independent positive predictive factors of complete clinical response to rituximab, constructing a parsimonious model with good calibration [&khgr;2 of 5.719 (d.f.=6, P=0.455)] and discrimination (C-statistic=0.739, 95% CI: 0.636–0.842). Conclusion After studying the pharmacogenetic role of TRAILR1/TRAIL polymorphisms in rituximab-treated FL patients, we found that the rs20575 CC genotype is an independent predictive factor of better rituximab response, indicating the possible involvement of death receptors in anti-CD20 mechanisms of action.

[1]  A. Hurtado,et al.  A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients , 2016, American journal of hematology.

[2]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Medeiros,et al.  The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette‐Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population , 2014, BJU international.

[4]  Yu-qin Pan,et al.  Association of the Polymorphisms in the Fas/FasL Promoter Regions with Cancer Susceptibility: A Systematic Review and Meta-Analysis of 52 Studies , 2014, PloS one.

[5]  V. Vicente,et al.  Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas , 2014, Annals of Hematology.

[6]  N. Schmitz,et al.  Suboptimal dosing of rituximab in male and female patients with DLBCL. , 2014, Blood.

[7]  T. Habermann.  Is rituximab one for all ages and each sex? , 2014, Blood.

[8]  Sonali M. Smith.  Dissecting follicular lymphoma: high versus low risk. , 2013, Hematology. American Society of Hematology. Education Program.

[9]  A. Rossi,et al.  Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study , 2013, Leukemia & lymphoma.

[10]  J. Cañete,et al.  Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. , 2012, Joint, bone, spine : revue du rhumatisme.

[11]  R. Greil,et al.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response , 2012, Haematologica.

[12]  V. Vicente,et al.  Role of GSTT1 and M1 null genotypes as risk factors for B‐cell lymphoma: Influence of geographical factors and occupational exposure , 2012, Molecular carcinogenesis.

[13]  Carsten Müller,et al.  The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. , 2012, Blood.

[14]  P. Kiely,et al.  BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. , 2011, Rheumatology.

[15]  Laura S. Jacobus,et al.  Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. , 2011, Blood.

[16]  B. Bonavida,et al.  A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells , 2011, Leukemia & lymphoma.

[17]  M. Hallek,et al.  Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies , 2011, Clinical Cancer Research.

[18]  P. Solal-Céligny,et al.  Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? , 2010, International journal of hematology.

[19]  G. Salles,et al.  Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Wei Zhang,et al.  Fcγ receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma , 2010 .

[21]  R. Mohammad,et al.  New targets for the treatment of follicular lymphoma , 2009, Journal of hematology & oncology.

[22]  M. Federico,et al.  Prognostic tools in follicular lymphomas , 2009, Expert review of hematology.

[23]  Jian Huang,et al.  A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma , 2008, Clinical Cancer Research.

[24]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Xuhui Zhou,et al.  The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. , 2008, The oncologist.

[26]  H. Marques,et al.  FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. , 2008, Cancer genetics and cytogenetics.

[27]  M. Tan,et al.  Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab , 2008, Leukemia & lymphoma.

[28]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[29]  D. Lawrence,et al.  Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. , 2007, Blood.

[30]  M. Czuczman,et al.  Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20 , 2007, Clinical Cancer Research.

[31]  R. Foà,et al.  FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab , 2007 .

[32]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Yeon-Hee Park,et al.  FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. , 2006, Blood.

[35]  Anton Hagenbeek,et al.  Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity , 2006, Clinical Cancer Research.

[36]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[37]  B. Bonavida,et al.  Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis , 2005, Oncogene.

[38]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[39]  P. Rutgeerts,et al.  Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[40]  L. Khawli,et al.  Generation of Rituximab Polymer May Cause Hyper-Cross-linking–Induced Apoptosis in Non-Hodgkin's Lymphomas , 2005, Clinical Cancer Research.

[41]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Colombat,et al.  Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.

[43]  D. Hicklin,et al.  Monoclonal antibody therapeutics and apoptosis , 2003, Oncogene.

[44]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[46]  R. Foà,et al.  Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. , 2002, Blood.

[47]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  T. Sauerbruch,et al.  Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. , 2000, Cellular immunology.

[49]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[50]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[51]  P. Krammer,et al.  Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. , 1996, Journal of immunology.

[52]  F. Cabanillas.  Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. P. Cid,et al.  Apoptosis. cáncer & Co , 2012 .

[54]  D. Maloney,et al.  Rituximab resistance. , 2011, Best practice & research. Clinical haematology.

[55]  M. Jarošová,et al.  FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. , 2011, Neoplasma.

[56]  Wei Zhang,et al.  Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. , 2010, Chinese medical journal.

[57]  E. Mini,et al.  Pharmacogenetics: implementing personalized medicine. , 2009, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[58]  G. Salles.  Clinical features, prognosis and treatment of follicular lymphoma. , 2007, Hematology. American Society of Hematology. Education Program.

[59]  R. Foà,et al.  FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. , 2007, Haematologica.

[60]  B. Bonavida,et al.  Respectively Resistance and Chemoresistance , in FasLActivity : Role of YY 1 and Bcl-x B κ Lymphoma Cell Line via Inhibition of NF-Expression in Ramos Non-Hodgkin ' sLBcl-x Rituximab-Induced Inhibition of YY 1 and Benjamin Bonavida , 2005 .